Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4

Xu, BingheBingheXuHu, XichunXichunHuLi, WeiWeiLiSun, TaoTaoSunShen, KunweiKunweiShenWang, ShusenShusenWangCheng, YingYingChengZhang, QingyuanQingyuanZhangCui, ShudeShudeCuiTong, ZhongshengZhongshengTongGeng, CuizhiCuizhiGengSong, ErweiErweiSongCHIUN-SHENG HUANGet al.,et al.2023-07-122023-07-122022-1109598049https://scholars.lib.ntu.edu.tw/handle/123456789/633540The cyclin-dependent kinase 4/6 inhibitor palbociclib has demonstrated efficacy and a manageable safety profile in combination with endocrine therapy in women with oestrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in international phase 3 trials. The phase 3 PALOMA-4 trial evaluated the efficacy and safety of palbociclib plus letrozole versus placebo plus letrozole in Asian women with ER+/HER2- ABC.enAdvanced breast cancer; Asian; Letrozole; Oestrogen receptor–positive; Palbociclib[SDGs]SDG3Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4journal article10.1016/j.ejca.2022.08.012361551172-s2.0-85138510141https://api.elsevier.com/content/abstract/scopus_id/85138510141